Three decades of genetic discoveries are accelerating the transition toward precision medicine in Parkinson disease by refining diagnostics, informing targeted therapies, and enabling genetically stratified clinical trials, according to a review published in Nature Reviews Neurology.
Parkinson disease is a complex and heterogeneous neurodegenerative disorder characterized by variable progression and treatment response. Genetic research over the past thirty years has identified a diverse genetic architecture that spans rare monogenic forms, strong genetic risk variants, and a large set of common and rare variants contributing variably to disease heritability.
These genetic findings have pinpointed critical biological mechanisms driving the neurodegenerative cascade. Specifically, investigations have identified protein misprocessing, mitochondrial dysfunction, lysosomal impairment, and altered immune system responses as primary drivers implicated in Parkinson disease biology.
Genome-wide association studies have identified more than 100 loci associated with Parkinson disease susceptibility. Researchers note that polygenic risk scores alongside gene-prioritization tools could enable accurate risk predictions and support the identification of novel druggable targets.
Genetic information is increasingly being integrated into clinical decision-making, patient counselling, and the identification of biologically distinct forms of Parkinson disease. In therapeutic development, these insights are guiding targeted strategies and informing the design of genetically stratified clinical trials.
Looking ahead, the integration of genetic profiling into multiomic frameworks holds potential to reveal novel biological subtypes of the disease that could receive targeted disease-modifying interventions. However, the translation into personalized care continues to navigate challenges including incomplete penetrance, variable disease expression, and missing heritability across multiple ancestries.
The review synthesizes three decades of research to map the evolution of Parkinson disease genetics, examining how genomic discoveries translate into clinical applications spanning diagnosis, prognosis, and the development of disease-modifying therapies. By tracing the historical progression of the field, the authors illustrate how uncovering the complex genetic architecture—ranging from rare monogenic forms to strong genetic risk factors and common variants with modest effects—has reshaped scientific understanding of disease biology.
Central to this translational framework is the direct link between identified genetic risk factors and the specific biological pathways implicated in the neurodegenerative process. The review focuses on four primary mechanisms driving neurodegeneration: protein misprocessing, mitochondrial dysfunction, lysosomal impairment, and altered immune system responses. Mapping these biological processes provides a concrete basis for therapeutic innovation, enabling researchers to connect specific genetic impairments with targeted treatment strategies designed to address the underlying neurodegenerative cascade.
At the genomic level, the identification of more than 100 loci through genome-wide association studies provides a broad foundation for understanding disease susceptibility. The review describes how computational approaches, specifically polygenic risk scores alongside gene-prioritization tools, are positioned to translate these numerous loci with modest individual effects into accurate disease risk predictions. Beyond risk assessment, these analytical tools serve a critical translational function by facilitating the identification of novel druggable targets. Prioritizing genes and loci in this manner helps bridge population-scale genomic associations with actionable targets for disease-modifying therapeutic development.
Within clinical settings, genetic insights are increasingly applied to support clinical decision-making and provide more accurate patient counselling. Looking ahead, the review emphasizes that integrating genetic profiling within multiomic frameworks will be critical to uncovering novel biological subtypes of the disease. Such biological stratification is expected to drive therapeutic innovation by enabling genetically stratified clinical trials, ensuring that emerging disease-modifying therapies are tested in patient groups defined by specific underlying biological mechanisms.
Despite these translational advancements, the review outlines several ongoing challenges that complicate the implementation of precision medicine in Parkinson disease. Overcoming these diagnostic and biological challenges by integrating genetic knowledge into ongoing research and clinical practice will be vital to establishing a comprehensive framework for personalized care and improving patient outcomes.
Subject of Research: Parkinson disease genetics and precision medicine translation
Article Title: Translating Parkinson disease genetics into clinical benefit
Article References: Avenali, M., Imarisio, A., & Valente, E. M. (2026). Translating Parkinson disease genetics into clinical benefit. Nature Reviews Neurology. https://doi.org/10.1038/s41582-026-01283-y
Image Credits: AI Generated
DOI: 10.1038/s41582-026-01283-y
Keywords: Parkinson disease, neurogenetics, precision medicine, disease-modifying therapies, genome-wide association studies, polygenic risk scores, mitochondrial dysfunction, lysosomal impairment, Translating, Parkinson, disease, genetics
